Kornimate/medical-research-clean huggingface dataset:
epigenorm antivir combined with acupuncture for the treatment of osteoarthritis patients who are overweight or obese

Conditions: Osteoarthritis; Overweight and Obesity

Summary: the study evaluates analgesic, antiinflammatory and metabolic effects of a supplement epigenome-antivir (extracts of glycyrrhiza roots, hippophae rhamnoides leaves, curcumin, green tea, and vitamin c) combined with acupuncture in patients with knee osteoarthritis (oa) and metabolic syndrome.

epigenome-antivir components have long been used in traditional medicine and have been shown to exert anti-inflammatory properties both in vitro and in vivo. it has also been shown that acupuncture can provide a moderate analgesic effect in osteoarthritis. it is anticipated that the combination of epigenome-antivir and acupuncture will reduce pain, inflammatory and metabolic markers in patients with oa and metabolic syndrome.

Eligibility criteria:
inclusion criteria: * osteoarthritis of the knee fulfilling american college of rheumatology (acr) criteria * bmi of 25 or more exclusion criteria: * use of nsaids one month prior to study entry (paracetamol is allowed) * pregnancy and lactation * increased sensitivity to the study drug * clinically significant renal function impairment * use of antidepressants * diagnosis of bipolar disorder * use of symptomatic slow acting drugs of oa (sysadoa) one month prior to study entry * any condition which may lead to difficulties to participation in the study from the viewpoint of investigator
natural history and patient journey in dementia: a nationwide linked electronic health records study of 5.6 million individuals.

Conditions: Dementia, Alzheimer, Electronic Health Records, Hospitalizations, Epidemiology, Comorbidity, United Kingdom, Incidence, Mortality, Cause of Death

Summary: the trajectory of dementia patients within the national health system and their recent temporal trends remains to be fully elucidated. to study the dementia incidence, mortality and case-fatality, we implemented a longitudinal cohort study with the linked electronic health records of 5.6 million population in the uk from 1998 to 2016 (caliber). a matched case-control study design was used to investigate the causes of hospitalization and death comparing individuals with and without incident dementia.


Eligibility criteria:
inclusion criteria: * we identify individuals aged 30 years or older and registered in the current primary care practice for at least one year. exclusion criteria: * individuals are excluded if they had a prior history of dementia before study entry.
e-learning: teaching of blindness prevention

Conditions: Teaching Technique

Summary: e-learning material increases the student knowledge level before the traditional class of blindness prevention and help to fix this information a short period (one month) after the class.


Eligibility criteria:
inclusion criteria: * being a medical student matriculated in the course of ophthalmology. this course is taught to fourth-year students at state university of campinas. exclusion criteria: -
carevive survivor care planning system in improving quality of life in breast cancer survivors

Conditions: Stage I Breast Cancer; Stage I Cervical Cancer; Stage I Ovarian Cancer; Stage I Uterine Corpus Cancer; Stage IA Breast Cancer; Stage IA Cervical Cancer; Stage IA Ovarian Cancer; Stage IA Uterine Corpus Cancer; Stage IB Breast Cancer; Stage IB Cervical Cancer; Stage IB Ovarian Cancer; Stage IB Uterine Corpus Cancer; Stage IC Ovarian Cancer; Stage II Breast Cancer; Stage II Cervical Cancer; Stage II Ovarian Cancer; Stage II Uterine Corpus Cancer; Stage IIA Breast Cancer; Stage IIA Cervical Cancer; Stage IIA Ovarian Cancer; Stage IIB Breast Cancer; Stage IIB Cervical Cancer; Stage IIB Ovarian Cancer; Stage IIC Ovarian Cancer; Stage III Breast Cancer; Stage III Cervical Cancer; Stage III Ovarian Cancer; Stage III Uterine Corpus Cancer; Stage IIIA Breast Cancer; Stage IIIA Cervical Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Breast Cancer; Stage IIIB Cervical Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Breast Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Uterine Corpus Cancer

Summary: this pilot clinical trial studies how well the carevive survivor care planning system works in improving quality of life in breast cancer survivors. a personalized survivor care plan includes a summary of a patient's cancer treatment and a customized survivor care plan and may provide beneficial information and resources.

primary objecties: i. to evaluate the feasibility of using the carevive survivor care planning system (scps) during the follow-up visit for breast oncology survivors treated in a university cancer center or a community medical center. ii. to evaluate survivors' perceptions of the usability of the carevive technology. iii. to evaluate their perceptions of the acceptability (perception of benefit) of the treatment summary and survivor care plan. secondary objectives: i. examine the psychometrics of surveys developed for this research. ii. compare participants' perceptions of the care received under the carevive system with clinician documentation. iii. compare clinician documentation of care received by this sample with documentation of care provided for historical controls at each site.

Eligibility criteria:
inclusion criteria: * prospective study: completed primary treatment for breast malignancies; receive survivorship care at thomas jefferson university (tju) or reading health system (rhs) * prospective study: individuals will have pathologically confirmed breast cancer (stages i-iii) * prospective study: able to understand and read english * prospective study: physically capable of using a tablet computer (no severe visual, hearing, or hand motor deficits) * retrospective chart review: individuals will have pathologically confirmed breast cancer or gynecological (gyn) malignancies including uterine, ovarian, or cervical cancers, stages i-iii; treated in the previous two years (2013-2014) exclusion criteria: * women who are pregnant * vulnerable populations: cognitively impaired; prisoners; terminally ill; elderly and infirm; drug addicts
the effects of inspiratory muscle training in children with cerebral palsy

Conditions: Cerebral Palsy

Summary: cerebral palsy (cp) is characterized by permanent or variable sensory-motor function impairments resulting from developmental anomalies or damage to the brain. spasticity, dystonia, postural disorders, and weakened movement patterns can hinder the development of the respiratory system in children with cp. as the severity of postural disorders increases in children with cp, inadequate or improper use of respiratory muscles and insufficient ventilation reduce the mobility of the thoracic cage. the aim of study is to investigate the effects of respiratory muscle training on respiratory parameters, trunk control, walking, and functional independence in children with cp.

in this prospective randomized controlled study, participants will be divided into two groups: the inspiratory muscle training (imt) group and the control group. the imt group will receive imt in addition to the traditional physical therapy program, while the control group will only receive the traditional physical therapy program. respiratory muscle strength, respiratory functions, chest expansion, trunk control, walking speed and endurance, and functional independence will be assessed before and after the training.

Eligibility criteria:
inclusion criteria: * aged between 4 and 12 years * classified as levels 1, 2, and 3 according to the gross motor function classification system (gmfcs) * diagnosed with spastic diplegia and/or hemiplegic cerebral palsy * ability to cooperate during the exercises exclusion criteria: * presence of acute or chronic respiratory diseases * presence of acute medical conditions * history of active epilepsy * scoliosis with a cobb angle greater than 30 degrees * presence of chest deformities * severe visual and hearing impairments

Keywords: respiratory function test muscle strength gait trunk
a study to investigate the safety and efficacy of kqb198 as monotherapy and in combination in participants with advanced hematologic malignancies

Conditions: Hematologic Malignancies; Adult

Summary: the goal of this clinical trial is to learn if kqb198 works to treat advanced hematologic malignancies in adults. it will also learn about the safety of kqb198. the main questions it aims to answer are: * what is the safe dose of kqb198 by itself or in combination with other anti-cancer drugs? * does kqb198 alone or in combination with other anti-cancer drugs decrease the size of the tumor? * what happens to kqb198 in the body? participants will: * take kqb198 daily, alone or in combination with another anti-cancer drug * visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that


Eligibility criteria:
inclusion criteria: * adequate organ function part 1 and part 2, cohort b participants only: • ph+ cml in chronic phase who have been previously treated with at least 2 different tyrosine kinase inhibitors (tkis) and are relapsed from or intolerant to those tkis and ineligible for alternative therapeutic options likely to produce clinical benefit as determined by the investigator. part 2, cohort a participants only: • participants with ph+ cml in chronic phase who are on dasatinib prior to study entry and have a warning or failure to dasatinib as determined by the investigator per eln 2020 guidelines exclusion criteria: * cml in accelerated or blast phase * prior therapy with a similar mechanism of action to kqb198 * history of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow * history of interstitial lung disease * cardiac abnormalities

Keywords: cml dasatinib
the effects of jnj-42165279 on the neural basis of anxiety disorders in healthy male volunteers

Conditions: Healthy

Summary: the purpose of this study is to evaluate the potential efficacy of jnj-42165279 in treating anxiety disorders through evaluation of brain activation patterns using imaging technology in healthy volunteers.

this is a single site, double-blind (neither investigator nor the participant knows the treatment that the participant receives) study. the study will consist of a screening phase (1-2 visits), a treatment phase (4 visits), and a post treatment phase (follow-up safety visit, 7 to 14 days after the last dose of the study drug). during the screening phase, participants will be evaluated to determine if they meet the study eligibility criteria, which will include collection of blood and urine samples. during the treatment phase, eligible participants will be assigned by chance (like a toss of a coin) to receive either jnj-42165279 100 mg or placebo once daily during 4 consecutive visits to the clinic. placebo is an inactive substance that is compared with a drug to test whether the drug has a real effect. the potential of the drug to treat anxiety will be assessed on day 4 of the treatment phase. the primary assessment, blood oxygen level dependent functional magnetic resonance imaging (bold-fmri), will measure brain activity patterns while participants complete 3 emotionally-provoking tasks. additionally, participants' startle responses (eye blinks) will be evaluated in two emotionally-provoking behavioral tasks outside of the scanner. questionnaires will be completed to evaluate participants' mood, and blood samples will be collected to measure concentrations of jnj-42165279 and biomarkers of drug activity. safety will be monitored throughout the study, including adverse events, vital signs (blood pressure and heart rate), 12-lead ecgs, physical examinations, clinical safety laboratories, evaluation of suicidal risk, and a walk and turn test. the total study duration will be approximately 46 days.

Eligibility criteria:
inclusion criteria * good general health * body mass index between 18 and 30 kg/m2 and body weight not less than 50 kg * must adhere to required contraception during and for 3 months after study * must agree to not donate sperm during and for 3 months after study * must agree to not donate blood during and for 1 month after study * able to speak and understand english fluently exclusion criteria: * clinically significant medical or psychiatric illness * any contraindication to magnetic resonance imaging * unable to pass hearing test * alcohol or substance abuse; excessive nicotine or caffeine use * recently received an investigational drug, vaccine, or invasive medical device * unable to abide by protocol restrictions on use of other medications

Keywords: healthy anxiety disorders anxiety modulation male
buteyko based remedial breathing therapy with children with asthma

Conditions: Asthma

Summary: a randomized, controlled trial to investigate the effects of a buteyko based remedial breathing therapy on children with asthma regarding to their symptoms, use of medication and lung function tests.


Eligibility criteria:
inclusion criteria: * signed informed consent of the parents * age 6- 15 years * information and consent of the consulting doctor * levels of asthma therapy 1-3 exclusion criteria: * participation in another study

Keywords: asthma buteyko remedial breathing children
p.f.c. sigma fixed versus p.f.c. rp mobile bearing total knee systems

Conditions: Osteoarthritis, Knee

Summary: this post-market clinical follow-up study was designed to compile long-term knee replacement outcomes of the pfc sigma fixed and pfc sigma mobile rotating platform (rp) knee systems. the first patient had surgery on november 8, 2001 and the final patient had surgery on july 29, 2005. there were 120 knees consented by a single site, which was the planned sample size in the study protocol, with 117 receiving one of the study devices. the study was terminated as the primary outcome was met and the investigator decided to conduct the study without sponsor support after 2009.

performance and safety will be assessed using the following surgeon and patient based outcome tools: 1. american knee society knee and function scores 2. knee society radiological analysis 3. oxford knee score 4. sf 12 score 5. anterior knee pain score specific objectives of the evaluation being to assess the following: 1. improvement in functional recovery 2. incidence of anterior knee pain 3. improvement in quality of life 4. incidence of tibial loosening 5. incidence of excessive polyethylene wear

Eligibility criteria:
inclusion criteria: 1. administrative - the patient or their authorised representative is able to understand the evaluation, is able to give voluntary written informed consent and will comply with the post operative follow up regime. 2. age - there are no restrictions relating to age of the patient. the patient's age must be considered suitable by the clinical investigator for a bi-compartmental or tri-compartmental knee arthroplasty using either of the two systems available in the evaluation. 3. sex - male or female (providing that they are not pregnant) may be recruited to the evaluation. 4. diagnosis - patients that require a tri-compartmental knee arthroplasty for primary surgical management of idiopathic osteoarthritis. 5. suitability - patients who in the opinion of the clinical investigator are considered to be suitable for treatment with a fixed or mobile bearing tibial knee system and are suitable for patella resurfacing. exclusion criteria: 1. patients with rheumatoid arthritis. 2. patients requiring revision total knee arthroplasty surgery. 3. patients with any tibial deformity requiring tibial component augmentation. 4. patients that in the opinion of the clinical investigators require a constrained prosthesis. 5. patients with a known history of poor compliance to medical treatment. 6. patients who are known drug or alcohol abusers. 7. patients with a pathology which in the opinion of the clinical investigator will adversely affect healing. 8. patients who are currently participating in another clinical evaluation. 9. patients with other disorders which in the opinion of the clinical investigator will / could impair rehabilitation. 10. contra-indications for use of the device, as detailed in the package insert.
dupilumab dose reduction in patients with controlled atopic eczema

Conditions: Atopic Dermatitis; Atopic Dermatitis Eczema

Summary: the goal of this randomized controlled trial is to study the (cost)effectiveness of extending the intervals between dupilumab doses in patients with well-controlled atopic eczema, while considering physician- and patient-reported disease severity, quality of life, and dupilumab serum trough levels. patients will be divided randomly into three groups, receiving dupilumab 300 mg every 2 weeks, every 3 weeks, or every 4 weeks. researchers will then compare the outcomes among these three groups.

while dupilumab is an effective treatment for atopic eczema, it is expensive and not without the risk of unwanted adverse events. aiming for the lowest possible dose is important. the currently approved dose is a single loading dose of 600 mg, followed by 300 mg every 2 weeks. however, there is evidence that the intervals between doses could be extended in disease-controlled patients while maintaining the same effectiveness. the objective of this study is to assess the (cost)effectiveness and safety of dupilumab dose reduction in patients with controlled atopic eczema. a multicenter, single-blinded, non-inferiority randomized controlled trial will be performed, that is embedded in the treatment of atopic eczema (treat) nl registry. adult patients who are already undergoing dupilumab treatment and meet the treat-to-target criteria will be assigned randomly to one of three groups: receiving dupilumab 300 mg every 2 weeks, every 3 weeks, or every 4 weeks. the study will cover a duration of 24 weeks, during which participants will have three hospital visits (at week 0, week 16 and week 24) and one telephone appointment (at week 8). these sessions will involve assessments of both physician and patient-reported disease severity, quality of life and the evaluation of dupilumab serum trough levels. please refer below for a comprehensive overview of the outcome measures.

Eligibility criteria:
inclusion criteria: * the subject is an adult, * has a diagnosis of ae, * receives dupilumab 300 mg q2w for the treatment of ae, * has controlled disease according to the treat-to-target criteria, * agrees to the possibility that the dosage of dupilumab will be lowered, * has voluntarily signed and dated an informed consent prior to any study related procedure. exclusion criteria: * the subjects uses or initiates another systemic immunomodulating therapy for ae or another diagnosis.

Keywords: dupilumab
fresh frozen plasma and plasmalyte ® for priming cardiopulmonary bypass in infants and children

Conditions: Congenital Heart Disease

Summary: coagulation abnormalities after pediatric open-heart surgery are complex and very often multifactorial. besides the cardiopulmonary bypass (cpb), the congenital pathology and the coagulation tests during cpb, the younger age has been the most significant risk factor for bleeding and transfusion requirements. in children the volume of pump priming is much higher compared with the patient's circulating blood volume. for this reason the cpb tubing system is primed with packed red blood cells and fresh frozen plasma (ffp) to avoid excessive hemodilution and induced coagulopathy. while this is routinely performed in neonates and small infants, the routine priming of cpb system with ffp has been questioned in several randomized prospective studies in older infants. however, the results of these studies are conflicting. moreover, they show methodological issues.


Eligibility criteria:
inclusion criteria: * children weighing between 7 and 15 kg and admitted to undergo open-heart surgery with cpb exclusion criteria: * patients with preoperative coagulation abnormalities * parental refusal * emergency surgery * patients with preoperative renal or hepatic dysfunction
comparison of postoperative sensitivity in posterior teeth using conventional and bulkfill composites

Conditions: Class I Dental Caries

Summary: the purpose of this study is to compare the onset and severity of pain and postoperative sensitivity in patients after using conventional nanohybrid and bulkfill composites null hypothesis: there is no significant difference in mean postoperative sensitivity exhibited with conventional nano-hybrid versus bulkfill composites in mandibular molars with class 1 cavity.

the study will include 79 patients with class 1 carious mandibular molars. teeth are divided into two groups based on composite placement techniques. in group 1, 39 patients are restored with conventional nanohybrid composites using an incremental layering technique. in group 2, 40 patients are restored with bulk-fill composites containing a single increment. after taking a brief history, informed consent will be taken from patients. the depth of the cavity will be determined using a periodontal probe not extending more than 3 mm. preoperatively, pulp vitality will be assessed using the cold thermal test. a preoperative radiograph will also be taken. a rubber dam will be used. the cavity will be prepared and a selective etch technique will be used. patients will be recalled after 24 hours and 1 week, thermal cold tests will be performed and a questionnaire containing the numerical rating scale will be given to each patient for evaluation of post-operative pain felt after 24 hours and 1 week.

Eligibility criteria:
inclusion criteria: - 1. patients with ages range from 18- 55 years. 2. male/ female. 3. mandibular molars with class 1 shallow-sized cavity with no history of pre-operative pain or sensitivity. 4. ability to understand the use of pain and sensitivity scale. 5. patients with adequate oral hygiene and willingness to participate in this study. exclusion criteria: - 1. patients with deep caries of tooth associated with pain and sensitivity. 2. patients who have consumed any type of medication before treatment. 3. periapical pathologies (periapical abscess, sinus tract, periapical cyst, pulpal abscess. 4. unfavorable location of the tooth, severe tooth malposition, and trismus.

Keywords: conventional nanohybrid composites, bulk fill composites
trial comparing pain in single-incision laparoscopic cholecystectomy versus conventional laparoscopic cholecystectomy

Conditions: Cholelithiasis; Choledocholithiasis; Cholecystolithiasis; Pancreatitis; Cholangitis

Summary: this study aims to evaluate post-operative pain in single-incision laparoscopic cholecystectomy (silc) versus the conventional four port technique (lc). the investigators hypothesize that silc is non-inferior in post-operative pain.

as above

Eligibility criteria:
inclusion criteria: * presence of symptomatic gallstones * american society of anesthesiologists (asa) score 1 or 2 * informed consent exclusion criteria: * active acute cholecystitis * previous open upper abdominal surgery * bleeding disorders